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A Single Amino Acid Change in the SPRY Domain of
Human Trim5 Leads to HIV-1 Restriction
a SPRY domain [15]. These different domains were ex-
changed between the two proteins. The chimeras HR3,
HR2, and HR1 contain the human Trim5 RING motif
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National Institute for Medical Research with progressively longer substitutions of rhesus C-ter-
minal residues. A reciprocal series was also made (RH3,The Ridgeway
Mill Hill RH2, and RH1) where parts of the rhesus Trim5 are
substituted by human sequences. Restriction was mea-London NW7 1AA
United Kingdom sured by a previously described two-color FACS assay
[13, 16]. Briefly, nonrestricting cells were transduced
with an MLV-based vector carrying the Trim gene and
EYFP. Two days posttransduction, the cells were chal-Summary
lenged with tester viruses incorporating various capsids
and encoding the EGFPmarker. The percentage of Trim/Retroviral restriction factors are cellular proteins that
interfere with retrovirus replication at a postpenetra- EYFP positive cells that were transduced with the EGFP
markerwas then scored against that of Trim/EYFPnega-tion, preintegration stage in the viral life cycle [1–3].
The first restriction activity described was the mouse tive cells. Restriction was expressed as a ratio of
EGFP, EYFP cells to EGFP, EYFP cells. A ratioFv1 gene [4]. Three different alleles of Fv1, capable of
restricting different murine leukaemia viruses (MLV), of less than or equal to 0.3 was taken as restriction,
whereas a ratio between 0.7 and 1 indicated the absencehave been characterized at the molecular level [5, 6].
Two further activities, Ref1, which acts on MLV, and of restriction. A typical result is shown in Figure 1A. As
observed previously, human Trim5 restricted N-MLVLv1, which acts on lentiviruses, have been identified
in other mammalian species [7–9]. Recently, it has and the L117Hmutant of N-MLV, but not B-MLV or HIV-1
[13]. Rhesus Trim5 restricted HIV-1 as well as N-MLV,become clear that Ref1 and Lv1 are encoded by the
same gene, Trim5, which inhibits retrovirus replica- but not B-MLVorN L117H. These restricting phenotypes
were used as standards for comparison with the restric-tion in a species-specific manner [10–14]. A series of
chimeras between the human and rhesus monkey tion profile of the chimeric molecules.
All chimeras could restrict N-MLV, but not B-MLV,Trim5 genes were created to map and identify these
specificity determinants. The Trim5 SPRY domain indicating that the proteins were still functional after
exchanging domains (Figure 1B). Substitution of thewas found to be responsible for targeting HIV-1 re-
striction. By contrast, N-MLV restriction appears de- SPRY domain from the human Trim5 with the rhesus
SPRY domain in HR3 is sufficient to confer restrictionpendent on both the coiled-coil domain and the SPRY
domain. A single amino acid substitution (R332P) in to HIV-1. The reciprocal chimera, where the SPRY of
rhesus Trim5was replaced with the human form (RH3),the human Trim5 can confer the ability to restrict
HIV-1, suggesting that small changes during evolution lost the ability to restrict HIV-1. This implied that the
SPRY domain of Trim5 was sufficient and necessarymay have profound effects on our susceptibility to
cross-species infection. for recognizing and restricting HIV-1. The determinants
for N-MLV restriction seemed to be more complex. Re-
placing the SPRY domain of rhesus Trim5 with theResults and Discussion
human form (RH3) enabled it to restrict N L117H in addi-
tion to N-MLV, implying that the SPRY domain was alsoHuman Trim5 restricts N-tropic MLV, but not B-tropic
MLV or HIV-1, whereas rhesus monkey Trim5 restricts involved in targeting the restriction of N-MLV. However,
substitution of the human SPRY domain with the corre-N-tropic MLV and HIV-1, but not B-tropic MLV [11–14].
The human and rhesus forms of Trim5 can also be sponding rhesus sequences (HR3) did not abolish its
ability to restrict N L117H. It was only when the coiled-distinguished by using the L117H mutation of N-MLV,
coil domain as well as the SPRY of human Trim5 waswhich is restricted by human, but not rhesus monkey
replaced with that from rhesus (HR2) that restriction ofTrim5 [13]. A series of chimeras between the human
N L117H was lost. These results suggested that bothand rhesus genewas constructed with overlapping PCR
the coiled-coil and the SPRY domains play roles in de-(Figure 1) to examine which domain of Trim5 was in-
termining the specificity of MLV restriction.volved in determining the specificity of retroviral restric-
Two more sets of chimeras were constructed (Figuretion. The structures of these chimeras (and all subse-
2) to further delineate the regions of the SPRY domainquent constructs) were confirmed by sequencing.
involved in restriction. HR4 to HR7 consisted of humanTrim5 has a modular design with a series of distinct
Trim5 with decreasing lengths of rhesus sequencesmotifs. These include the RING motif, a B-Box, and a
substituted within the SPRY domain, whereas RH4 tocoiled-coil domain, which together form the tripartite
RH7 formed a reciprocal series where the rhesus Trim5RBCC domain characterizing Trim proteins, as well as
was substituted with human SPRY sequences. As ex-
pected, all the chimeras could restrict N-MLV, but not*Correspondence: jstoye@nimr.mrc.ac.uk
B-MLV, indicating that they were functional with respect1Present address: CNRS UPR 9051, Centre Hayem, Hoˆpital Saint-
Louis, 16, rue de la Grange-aux-Belles, 75010 Paris, France. to restriction. HR4 was able to restrict HIV-1, but the
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Figure 1. Restriction of HIV-1 and MLV by
Human, Rhesus, and Chimeric Trim5
(A) Graphical representation of restriction by
human and rhesus Trim5. HT1080 and M.
dunni cells were transduced with MLV-based
vectors carrying Trim5 and EYFP at a multi-
plicity of infection of 1. Two daysposttransduc-
tion, HT1080 cells were challenged with HIV-1
vectors carrying EGFP, whereasM. dunni cells
were challenged with either N-MLV, B-MLV,
or N L117H. The ratio of the percentage of
Trim5 cells versus that of Trim5 cells
that were infected was determined by FACS
analysis 2 days after challenging with tester
virus. A ratio of between 0.7 to 1 indicates
the absence of restriction, whereas a ratio of
less than 0.3 indicates the presence of re-
striction. Error bars represent the standard
error of the mean.
(B) Schematic representation of the human/
rhesus chimeric Trim5 constructs and their
ability to restrict HIV-1, N-MLV, B-MLV, and
N L117H. Restriction assays were performed
as described in (A). White boxes indicate hu-
man derived sequences; gray boxes show
rhesus monkey sequences. The amino acid
positions corresponding to the humanTrim5
are indicated on the top of the figure, whereas
the ones corresponding to the rhesus se-
quence are indicated at the bottom.
restriction was absent when the rhesus sequences after We next sought to identify individual residues be-
tween amino acids 322 and 374 in the SPRY domainresidue 374 were replaced with human ones from HR5
to HR7. This suggested that the region determining that affected restriction. Between the human and rhesus
sequence, there was a difference of seven amino acids,specificity for HIV-1 restriction was between amino
acids 322 to 374 of the rhesus Trim5. RH4, which does two contiguous, the others scattered throughout the
region. In addition, a stretch of six residues starting fromnot restrict HIV-1, lacked the rhesus sequence in this
region. When the rhesus sequence was included in the amino acid 335 in the human sequence was replaced
by 8 different residues in the rhesus sequence. The resi-chimera RH5, restriction of HIV-1 was restored, confirm-
ing the requirement of this region in HIV-1 recognition dues at these positions in the human Trim5 were re-
placed with the corresponding residues from rhesusand restriction. The requirements for MLV restriction
were found to be somewhat different from that of HIV-1. monkey by site-directed mutagenesis. The mutants
were then assayed for restriction of HIV-1 and MLV (Fig-HR4 to HR7 could restrict N L117H. This was expected
as both humanTrim5 andHR3 (Figure 1B) could restrict ure 3). Only two positions in this region affected restric-
tion to HIV-1. The arginine to proline change at residuethis mutant. The chimeras RH4 to RH7 (Figure 2) contain
decreasing amount of human SPRY sequences com- 332 and the exchange of the six human residues at
position 335 for the eight amino acid rhesus sequencepared to RH3 (Figure 1B). RH4 and RH5 could restrict
N L117H, but the restriction was abolished when human conferred the ability to restrict HIV-1 to the human
Trim5. Conversely, changing each of these positionsresidues before amino acid 401 were excluded, in RH6
and RH7. This suggested that the SPRY region in human in the rhesus Trim5 to the corresponding residues in
the human protein did not abolish restriction of HIV-1.Trim5 influencing N-MLV restriction involved residues
up to amino acid 400. Taken with the previous data, Indeed, when both positions of the human protein were
substituted by the rhesus residues, the resulting doublethese results indicated that the specificity determinants
of MLV restriction encompassed a region somewhat mutant had a restricting phenotype that was similar to
the two single mutants. This suggested that both oflarger than that which governed HIV-1 restriction.
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Figure 2. Restriction by Human/Rhesus
Monkey Trim5 SPRY Domain Chimeras
Structures of the chimeras made are shown
on the left; their restriction properties on the
right. The amino acid positions correspond-
ing to the human Trim5 protein are indicated
above the constructs, whereas the ones cor-
responding to the rhesus sequence are indi-
cated at the bottom. Restriction assays were
performed and scored as described for Fig-
ure 1.
these positions contributed to the restriction and that in the human Trim5 might be contributing degenerately
to restricting N L117H. Indeed, this could involve se-they might be degenerate. Hence, the loss of one of
these positions could be compensated by the presence quences found in the coiled-coil region (Figure 1B).
We have previously shown that Trim1 could also re-of the other.
The corresponding change from proline to arginine in strict N-MLV, but not HIV-1 [13]. Like Trim5, it consists
of an SPRYdomain after the tripartite RBCCmotif. Trim1position 334 in the rhesus protein did not confer restric-
tion to N L117H, suggesting that unlike HIV-1 restriction, was first identified as a homolog of the Opitz syndrome
gene Trim18 (Mid1) to which it showed 83% similaritythis position was not involved in MLV restriction. Ex-
changing the eight residues at position 337 of the rhesus at the amino acid level [17, 18]. However Trim18, unlike
Trim1, does not restrict N-MLV (Figure 4). Formally, thisproteinwith the six found in humans resulted in the restric-
tion of N L117H, suggesting that the position was involved might be due to a lack of protein expression. Alterna-
tively, it provides a further opportunity to examine thein MLV restriction. However, corresponding changes in
thehumansequence to the rhesus residuesdidnot abolish role of the SPRY domain in retroviral restriction. The
C-terminal portion of African green monkey Trim1,restriction of N L117H. This suggests that other regions
Figure 3. Effects of Specific Amino Acid Changes within the SPRY Domain on the Restriction of HIV-1 and MLV
The altered sequences of the SPRY domain are shown on the left, whereas the restriction properties of the variants are shown on the right.
Restriction assays were performed and scored as described for Figure 1.
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Figure 4. Restriction of MLV by African
Green Monkey Trim1/Trim18 Chimeras
Residues 314 to 715 of Vero Trim1 were re-
placed with residues 314 to 667 of Vero Trim18
to form Vero Trim1/Trim18. Vero Trim18/Trim1
was constructed by replacing residues 314
to 667 of Vero Trim18 with residues 314 to
715 of Vero Trim1. Trim1 sequences are rep-
resented by white boxes, whereas Trim18 se-
quences are colored gray on the left. The abil-
ity to restrict is shown in the table on the
right. Restriction assays were performed and
scored as described for Figure 1.
cloned from Vero cells, was used to replace the corre- OMK Trim5 (V6), which contained the owl monkey
SPRY domain in place of CypA, was inactive againstsponding region in Trim18 beginning from residue 314
(Figure 4). This chimera (Vero Trim18/Trim1) was active both HIV-1 and MLV [20]. To further probe the role of
SPRY in CA recognition and binding, we asked if theagainst N-MLV as well as N-MLV containing the N82D
mutation, but not B-MLV, a restriction phenotype typical SPRY domain from rhesus Trim5 could rescue the re-
striction activity of OMK Trim5 V6. Replacing the SPRYof Trim1. The reciprocal chimera Vero Trim1/Trim18 did
not restrict N-MLV and N N82D. Taken together, these of OMK Trim5 V6 in OMKRhSPRY with that from rhesus
restored its activity against HIV-1 (Figure 5), suggestingresults provided further evidence for the involvement
of the SPRY domain as the recognition domain in the that this domain alone could account for the targeting
of HIV-1 CA. However, OMKRhSPRY was not activeprocess of retroviral restriction.
In owlmonkeys, a psuedogeneencoding the cyclophi- against N-MLV. Intriguingly, the sequence of the coiled-
coil domain of OMK Trim5 is very different from that oflin A (CypA) protein is inserted within the seventh intron
of the Trim5 gene [19, 20]. It is thought that the cyclo- the rhesus protein. In the light of the earlier result (Figure
1) suggesting the involvement of the coiled-coil domainsporine A (CsA) sensitive Lv1 activity of OMK cells [21]
can be explained by the presence of a fusion protein in in MLV restriction, the failure of OMKRhSPRY to restrict
might be due to the lack of MLV CA recognition se-which most of the Trim5 SPRY domain is replaced by
CypA [19, 20]. This implies that the function provided quences in the coiled-coil domain of OMK Trim5.
Our results indicate that the SPRY domain is the pri-by SPRY can be replaced by CypA; because CypA is
known to bind HIV-1 CA in a CsA sensitive manner [22], mary determinant of restriction specificity and suggest
that this specificity might be mediated through SPRYthis suggests that SPRY is providing binding as well as
specificity functions. To examine this idea further, we binding of capsid. TheSPRYdomainwas originally char-
acterized in proteins that regulated intracellular signal-replaced the SPRY domain of human and rhesus Trim5s
with the CypA insertion of the OMK Trim5 gene (Figure ing [23]. It can occur as a subdomain within the B30.2
domain [24], which is also found in Trim1 and Trim185). Both novel chimeras restricted wild-type HIV-1 (Fig-
ure 5), but not a mutant form that is not bound by CypA, [17, 18]. Although often associated with Trim proteins,
SPRY domains are also found in unrelated proteins suchCAG89V. In addition, the substitutions abolishedactivity
against N-MLV, which does not bind CypA [22]. Replac- as venom toxins and proteins with immunoglobulin-like
folds [24]. The functions of B30.2 and SPRY domainsing the SPRY domain of Trim5 from African greenmon-
key yielded identical results (data not shown). This con- are still not known but might include specific protein-
protein interactions. Our studies suggest that in Trimfirmed that CypA was performing the function of CA
recognition and binding in OMK Trim5-CypA. proteins, they play a crucial role in the interaction with
infectious agents such as retroviruses to abolish infec-We have previously found that an artificially created
Figure 5. Restriction Properties of Chimeric
Human, Rhesus, and Owl Monkey Trim5
A schematic representation of the chimeras
is presented on the left, whereas their ability
to restrict HIV-1 and MLV is shown on the
right. HuCypA and RhCypA were constructed
by replacing the human SPRY domain (resi-
dues 295 to 493) or rhesus SPRYdomain (res-
idues 297 to 497) with the cyclophilin A inser-
tion in OMK Trim5 V4 (residues 296 to 474).
OMKRhSRPY was made by replacing the
OMK SPRY of V6 (residues 296 to 495) with
the rhesus SPRY domain (residues 297 to
497). Human sequences are represented by
white boxes, whereas rhesus and owl mon-
key sequences are represented by light and
dark gray boxes, respectively. Restriction
assays were performed and scored as de-
scribed for Figure 1.
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